Display options
Cite
Osterlund P, Peltonen R, Alanko T, et al. A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection. Onco Targets Ther. 2014;7:1177-84doi: 10.2147/OTT.S63739.
Osterlund, P., Peltonen, R., Alanko, T., Bono, P., & Isoniemi, H. (2014). A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection. OncoTargets and therapy, 71177-84. https://doi.org/10.2147/OTT.S63739
Osterlund, Pia, et al. "A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection." OncoTargets and therapy vol. 7 (2014): 1177-84. doi: https://doi.org/10.2147/OTT.S63739
Osterlund P, Peltonen R, Alanko T, Bono P, Isoniemi H. A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection. Onco Targets Ther. 2014 Jul 01;7:1177-84. doi: 10.2147/OTT.S63739. eCollection 2014. PMID: 25061319; PMCID: PMC4085307.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2014 Jul 01;7:1177-84. doi: 10.2147/OTT.S63739. eCollection 2014.

A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection.

OncoTargets and therapy

Pia Osterlund, Reetta Peltonen, Tuomo Alanko, Petri Bono, Helena Isoniemi

Affiliations

  1. Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland ; Institute of Clinical Medicine, University of Helsinki, Helsinki, Finland.
  2. Institute of Clinical Medicine, University of Helsinki, Helsinki, Finland ; Department of Surgery, Helsinki University Central Hospital, Helsinki, Finland.
  3. Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.

PMID: 25061319 PMCID: PMC4085307 DOI: 10.2147/OTT.S63739

Abstract

BACKGROUND: Bevacizumab is active in the treatment of metastatic colorectal cancer (mCRC). However, efficacy of bevacizumab has predominantly been evaluated on selected patients with relatively good performance status and minor comorbidities. We evaluated the efficacy and safety of bevacizumab in unselected patients with mCRC, some of whom underwent liver resection.

MATERIAL AND METHODS: All patients with inoperable mCRC, fit for combination chemotherapy (n=180), who were initially not resectable, not included into studies and without contraindications to bevacizumab, and initiated on bevacizumab at the Helsinki University Central Hospital between April 2004 and December 2005 were included (n=114). Most (n=70) received 5-fluorouracil/leucovorin/irinotecan plus bevacizumab as first-line therapy. The remainder (n=44) of the patients received bevacizumab in combination with oxaliplatin or irinotecan with or without 5-fluorouracil or capecitabine. Minimum follow-up was 7 years. Treatment response was evaluated every 8-10 weeks according to RECIST criteria.

RESULTS: Median age was 59.6 years (range 35-79); male/female ratio was 54%/46%; World Health Organization performance status 0/1/2-3 was 33%/55%/11%, respectively; and the number of metastatic sites, one/two/three or more, was 31%/21%/48%, respectively. Median duration of bevacizumab therapy was 7.8 months (range 0.5-70.5 with pauses). In first-line (n=40), response rate (RR) was 62%, progression-free survival (PFS) 11.7 months, and overall survival (OS) 22.1 months. In second-line (n=43), RR was 44%, PFS 8.7 months, and OS 18.7 months. In later lines (n=31), RR was 14%, PFS 6.7 months, and OS 14.2 months. Ten patients with initially unresectable liver metastases became operable and R0 resection was achieved in 90% (9/10 resections). In 23% (7/31) of operated metastases, no vital tumor cells were found in histologic examination. Operative morbidity was low: two mild infections, no increased bleeding tendency was noticed, and no impaired wound healing occurred.

DISCUSSION: Bevacizumab-containing combination therapy was effective with acceptable tolerability in an unselected mCRC patient population in which liver resections could be safely performed.

Keywords: colorectal cancer; everyday clinical practice; liver resection; metastatic

References

  1. N Engl J Med. 2004 Jun 3;350(23):2335-42 - PubMed
  2. J Clin Oncol. 2008 Apr 10;26(11):1830-5 - PubMed
  3. Oncology. 2009;77(2):113-9 - PubMed
  4. Ann Surg Oncol. 2007 Feb;14(2):759-65 - PubMed
  5. J Clin Oncol. 2008 Apr 20;26(12):2013-9 - PubMed
  6. Oncologist. 2009 Sep;14(9):862-70 - PubMed
  7. J Clin Oncol. 2007 Apr 20;25(12):1539-44 - PubMed
  8. Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1295-8 - PubMed
  9. J Clin Oncol. 2005 Jun 1;23(16):3706-12 - PubMed
  10. J Surg Oncol. 2005 Sep 1;91(3):173-80 - PubMed
  11. J Clin Oncol. 2008 Nov 20;26(33):5326-34 - PubMed
  12. Ann Oncol. 2009 Nov;20(11):1842-7 - PubMed
  13. Lancet Oncol. 2013 Jan;14(1):29-37 - PubMed
  14. Oncologist. 2012;17(12):1486-95 - PubMed

Publication Types